Umer Raffat
Stock Analyst at Evercore ISI Group
(0.97)
# 3,530
Out of 4,829 analysts
21
Total ratings
50%
Success rate
-10.26%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Initiates: Outperform | n/a | $26.38 | - | 1 | Feb 25, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $14.93 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $4.60 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $1.71 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $0.88 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $31.27 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $13.15 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $17.96 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $3.15 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $15.01 | - | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $32.38 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.71 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.13 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $0.17 | +27,726.09% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $274.76 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $6.83 | +602.78% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $103.58 | - | 1 | Feb 23, 2017 |
Metsera
Feb 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $26.38
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $14.93
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $4.60
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.71
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.88
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $31.27
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $13.15
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $17.96
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $3.15
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.01
Upside: -
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $32.38
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.71
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.13
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $48
Current: $0.17
Upside: +27,726.09%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $274.76
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $6.83
Upside: +602.78%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $103.58
Upside: -